Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

被引：0
|
作者：
Qin, Shukui
Bai, Yuxian
Wang, Zishu
Chen, Zhendong
Xu, Ruihua
Xu, Jianming
Zhang, Hongmei
Chen, Jia
Yuan, Ying
Liu, Tianshu
Yang, Lin
Zhong, Haijun
Chen, Donghui
Shen, Lin
Hao, Chunyi
Fu, Deliang
Cheng, Ying
Yang, Jianwei
Bai, Xian Hong
Li, Jin
机构：
[1] Jinling Hosp, Ctr Canc, Dept Med Oncol, Nanjing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[4] Anhui Med Univ, Hosp 2, Hefei, Anhui, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[6] Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China
[7] Air Force Med Univ PLA, Xijing Hosp, Xian, Peoples R China
[8] Jiangsu Canc Hosp, Dept Oncol, Nanjing, Peoples R China
[9] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China
[10] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[12] Univ Chinese Acad Sci, Chinese Acad Sci, Dept Med Oncol, Zhejiang Canc Hosp,Inst Canc & Basic Med,Canc Hos, Hangzhou, Peoples R China
[13] Shanghai Jiao Tong Univ, Peoples Hosp 1, Sch Med, Dept Oncol, Shanghai, Peoples R China
[14] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[15] Beijing Canc Hosp, Beijing, Peoples R China
[16] Fudan Univ, Pancreat Dis Inst, Huashan Hosp, Dept Pancreat Surg, Shanghai, Peoples R China
[17] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[18] Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Abdominal Oncol, Fuzhou, Peoples R China
[19] Biotech Pharmaceut Ltd Corp, Beijing, Peoples R China
[20] Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4011
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
    Qin, Shukui
    Li, Jin
    Bai, Yuxian
    Wang, Zishu
    Chen, Zhendong
    Xu, Ruihua
    Xu, Jianming
    Zhang, Hongmei
    Chen, Jia
    Yuan, Ying
    Liu, Tianshu
    Yang, Lin
    Zhong, Haijun
    Chen, Donghui
    Shen, Lin
    Hao, Chunyi
    Fu, Deliang
    Cheng, Ying
    Yang, Jianwei
    Wang, Qiong
    Qin, Baoli
    Pan, Hongming
    Zhang, Jun
    Bai, Xianhong
    Zheng, Qingshan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5163 - +
  • [2] Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China
    Long, Rong
    Guo, Hao
    Chen, Kun
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [3] Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
    Sun, Yan
    Hu, Chaosu
    Lin, Qin
    Gao, Li
    Wang, Jianhua
    Zhu, Xiaodong
    Hao, Junfang
    Lang, Jin Yi
    Wang, Peiguo
    Ye, Ming
    Li, Xia
    Xu, Benhua
    Wu, Rong
    Bai, Chunmei
    You, Qingshan
    Chen, Xiaozhong
    Wang, Jun
    Hu, Desheng
    Wu, Gang
    Pan, Jian-Ji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Gemcitabine versus mitomycin versus gemcitabine/mitomycin in the treatment of locally advanced and metastatic pancreatic cancer - a randomized multicenter phase II trial
    Block, A.
    Tuinmann, G.
    Boehlke, I
    Mueller, L.
    Lipp, R.
    Porschen, R.
    von Hielmcrone, K.
    Pietsch, M.
    Schulte, F.
    Nissen, S-O
    Pichlmeier, U.
    Hossfeld, D. K.
    Bokemeyer, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 36 - 37
  • [5] Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients
    Hong, Jung Yong
    Nam, Eun Mi
    Lee, Jeeyun
    Park, Joon Oh
    Lee, Sang-Cheol
    Song, Seo-Young
    Choi, Seong Ho
    Heo, Jin Seok
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 125 - 130
  • [6] Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients
    Jung Yong Hong
    Eun Mi Nam
    Jeeyun Lee
    Joon Oh Park
    Sang-Cheol Lee
    Seo-Young Song
    Seong Ho Choi
    Jin Seok Heo
    Se Hoon Park
    Ho Yeong Lim
    Won Ki Kang
    Young Suk Park
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 125 - 130
  • [7] A randomized phase II study comparing gemcitabine plus nadroparine versus gemcitabine in patients with locally advanced or metastatic pancreatic carcinoma: The GEMFRAX trial.
    Voorthuizen, T. V.
    Vervenne, W. L.
    Van Daalen, E. H.
    Phoa, S. S.
    Gouma, D. J.
    Bruno, M. J.
    Richel, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 205S - 205S
  • [8] Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.
    Demols, Anne
    Borbath, Ivan
    Van den Eynde, Marc
    Houbiers, Ghislain
    Peeters, Marc
    Marechal, Raphael
    Delaunoit, Thierry
    Goeminne, Jean Charles
    Laurent, Stephanie
    Holbrechts, Stephane
    Paesmans, Marianne
    Van Laethem, Jean L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
    Ko, Andrew H.
    Murphy, Patrick B.
    Peyton, James D.
    Shipley, Dianna L.
    Al-Hazzouri, Ahmed
    Rodriguez, Francisco A.
    Womack, Mark S.
    Xiong, Henry Q.
    Waterhouse, David M.
    Tempero, Margaret A.
    Guo, Shuangli
    Lane, Cassie M.
    Earwood, Chris
    DeBusk, Laura M.
    Bendell, Johanna C.
    ONCOLOGIST, 2017, 22 (12): : 1427 - +
12345